エノキサパリンナトリウム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Warning

• 危険有害性情報

  H317：アレルギー性皮膚反応を起こすおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P272：汚染された作業衣は作業場から出さないこと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P302+P352：皮膚に付着した場合：多量の水と石鹸で洗うこと。

  P321：特別な処置が必要である（このラベルの．．． を見よ）。

  P333+P313：皮膚刺激または発疹が生じた場合：医師の診断/手当てを 受けること。

  P363：汚染された衣類を再使用す場合には洗濯をすること。

  P501：内容物/容器を．．．に廃棄すること。

エノキサパリンナトリウム 価格

エノキサパリンナトリウム 化学特性,用途語,生産方法

• 説明

  Enoxaparin sodium is the sodium salt of a low-molecular-mass heparin that is obtained by alkaline depolymerisation of the benzyl ester derivative of heparin from porcine intestinal mucosa. Enoxaparin sodium is an antithrombotic agent (ATC code B01AB05) characterized by a higher ratio of antithrombotic activity to anticoagulant activity compared to unfractionated heparin.
  Specifically, Enoxaparin sodium as the sodium salt of depolymerized Heparin is subject to characteristic structural modifications from the effects of the depolymerization reaction. Characteristic structures such as partial transformation of glucosamines into mannosamines, formation of 1,6-anydro derivatives and 2,3 epoxide residues with subsequent conversion to galacturonic acid and the change in the proportion of the sulfated and non-sulfated residues are some of the changes that constitute Enoxaparin a structurally difficult to characterize molecule. As such no single technique or parameter is adequate to fully characterize the Enoxaparin molecule as part of a biosimilarity exercise against the reference.

• 化学的特性

  degree of sulphatation is ~ 2 per disaccharide

• 使用

  Enoxaparin is marketed under the brand name Lovenox and as a generic drug under the name enoxaparin sodium for injection.
  Enoxaparin sodium is intended for use in the treatment of deep vein thrombosis; prophylaxis of ischemic complications of unstable angina and non-Q-wave myocardial infarction, and treatment of acute deep vein thrombosis.

• 適応症

  Enoxaparin sodium is a gold standard for antithrombosis which has the largest number of indications among all LMWHs. Prophylaxis of vein thrombosis diseases (prevent intra-vein thrombosis), treatment of deep venous thrombosis, Prevention of thrombus formation in the in vitro circulation during hemodialysis, treatment of acute unstable angina and non-Q-wave myocardial infarction, administered with Aspirin.

エノキサパリンナトリウム 生産企業

Global(115)Suppliers

679809-58-6, エノキサパリンナトリウム キーワード